Haem.io
← Full deck

Haem.io

Intelligent Diagnostics for Precision Haematology

3-Minute Investor Pitch | £750,000 Seed Round

Haem.io

Intelligent Diagnostics for Precision Haematology

3-Minute Investor Pitch | £750,000 Seed Round

The Problem

Haematology diagnosis is too slow and too complex

Days to Weeks
Current diagnosis time
200+
Blood cancer subtypes
60+
Genetic markers to integrate

Unstructured Data

Genetics, cytogenetics, flow cytometry, morphology, and clinical context arrive in fragmented formats.

→

Manual Synthesis

Clinicians spend hours extracting facts before diagnostic reasoning can even begin.

→

Complex Guidelines

WHO 2022 and ICC 2022 contain hundreds of interconnected pathways that are hard to apply consistently.

This is not just workflow friction. In acute blood cancers, time changes outcomes.

The Solution

AI extraction plus formal diagnostic logic

Haem.io turns unstructured lab reports into explainable classification, risk stratification, guideline-aligned decision support, and clinical trial matching in minutes.

1Upload unstructured lab report
→
2AI extracts clinical facts
→
3Logic engine applies WHO + ICC
→
4Traceable decision support
~2 minutes · Explainable · Clinically auditable
Before
Hours to Weeks
Manual diagnosis process
→
With Haem.io
~2 Minutes
Clinician-in-the-loop decision support

Product Proof

Production beta, simplified workflow, auditable output

Classification results
Current status

Production beta with 10 haematologists

AML and MDS classifiers are built and being tested before formal NHS pilot validation.

What investors need to see

  • AI extraction: unstructured reports become clean clinical and molecular facts.
  • Formal logic: WHO 2022 and ICC 2022 pathways are applied consistently.
  • Full trace: every output can be reviewed by the clinician.

Business Model + Market

Bottom-up NHS wedge, oncology expansion upside

Annual SaaS licensing

NHS Trusts

£50k-£100k/year

Private Hospitals

£75k-£150k/year

Diagnostic Labs

£100k-£200k/year

NHS trusts already outsource complex cases at significant cost. Haem.io turns that spend into faster local specialist-grade decision support.

Why haematology first

Hardest diagnostic edge case in oncology

Hundreds of subtypes, dozens of mutations, and dual international guidelines make blood cancers the right first market.

1.2M
blood cancer diagnoses / year globally
£30B
AI medical diagnostics market by 2034
Expansion path: AML/MDS → other blood cancers → genomics-driven solid tumours.

Clinical Validation

Endorsed by leading NHS haematologists

"Haem.io has the potential to transform diagnosis and decision making for patients with haematological malignancies across the NHS."
Prof Charles Craddock CBEChair, UK AML Research Network
"Haem.io has the potential to revolutionise the quality of care that patients receive."
Dr John ChadwickThe Christie NHS Foundation Trust
"A real step forward in what technology can offer in supporting clinicians to make accurate clinical diagnoses."
Dr Tom CoatsRoyal Devon & Exeter NHS Trust
"I would wholeheartedly recommend this platform. This will be of significant use for clinicians in the front line."
Dr P A CahalinBlackpool Teaching Hospitals NHS Trust
4 Letters of Support•Letter of Intent for Pilot Study•3 NHS Trusts in pipeline

The Team

Founder-market fit across AI, haematology, and NHS diagnostics

Robert Lee

Robert Lee

CEO & Co-Founder

BSc Computer Science, Manchester. Cancer survivor and former Coinbase, LSEG, and FlexTrade engineer. Leads software, regulatory pathway, and research coordination.

Dr. Daniel Clarke

Dr. Daniel Clarke

CTO & Co-Founder

PhD Physics, University of Manchester and CERN. Former UK Civil Service statistician. Leads cloud architecture, AI strategy, and secure data systems.

Dr. John Burthem

Dr. John Burthem

Chief Medical Officer & Co-Founder

FRCP, FRCPath. Senior NHS consultant at Manchester Foundation Trust and lead of a regional diagnostic service for haematological malignancies.

Dr. Luke Carter-Brzezinski

Dr. Luke Carter-Brzezinski

Clinical Director & Co-Founder

Consultant Haematologist at MFT's Regional Diagnostic Service. Leads clinical outreach, validation strategy, and real-world workflow feedback.

Clinical logic co-developed directly with specialist NHS haematologists and translated into auditable software.

The Ask

£750k seed round. 18 months to Series A.

£750,000

Seed Investment | 18-Month Runway

Team

CEO & Lead Engineer£165k
Compliance Officer£105k
Clinical Validation Lead£90k
Commercial/Sales Lead£60k
£420k

Regulatory & Pilots

Class I registration & compliance£40k
4 NHS pilot studies£80k
£120k

Operations

Cloud, AI compute, legal, insurance£90k
Contingency buffer£120k
£210k
Months 1-6
Complete Class I registration. Launch first 2 NHS pilot studies.
Months 6-12
Complete pilot validations. First paying customers.
Months 12-18
5+ NHS trust contracts. Series A ready.

Series A unlock: regulatory registration + NHS validation + first paid contracts = a repeatable commercial platform for haematology and genomic oncology.

Haem.io

Precision diagnostics for every haematologist, everywhere.
Built by clinicians. Powered by AI. Explainable by design.

Global standards. Production beta. Ready for NHS validation.
Raising £750,000 to transform haematology diagnosis
robert.lee@haem.iohaem.io